CD274 and esophageal squamous cell carcinoma: Programmed death-ligand 1 (PD-L1) expression can be found in up to 40–50% of ESCC [38]; targeted agents such as pembrolizumab [14] and nivolumab [15] have shown promising results in ESCC [38,39].